1
|
Liu P, Xu X, Wang Y, Long X, Li X, Peng H. Effects of sodium thiosulfate on serum calcification factors in patients undergoing maintenance hemodialysis. Ther Apher Dial 2023; 27:1079-1087. [PMID: 37424269 DOI: 10.1111/1744-9987.14029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 05/29/2023] [Accepted: 06/13/2023] [Indexed: 07/11/2023]
Abstract
OBJECTIVE To investigate the effect of sodium thiosulfate (STS) on serum calcification factors in patients undergoing maintenance hemodialysis. METHODS Forty-four Patients were randomly divided into control group (n = 22) and observation group (n = 22) by envelope method (block 4 randomization). The control group received routine treatment while observation group was treated with STS on the basis of routine treatment. The biochemical indicators, including BUN, UA, SCr, Ca2+ , P3- , calcium-phosphorus product, PTH, hs-CRP, TG, TC, HDL, LDL, and serum calcification factor MGP, FA, FGF-23, and OPG levels were compared before and after treatment. RESULTS Control group had no statistically significant difference in the levels of vascular calcification factors MGP, FA, FGF-23, and OPG before and after treatment (p > 0.05). Whereas observation group had higher levels of MGP and FA, and lower levels of FGF-23 and OPG after treatment than before treatment (p < 0.05). The levels of MGP and FA in observation group were higher than those in control group, and FGF-23 and OPG were lower than those in control group (p < 0.05). CONCLUSION It is speculated that sodium thiosulfate can alleviate the progression of vascular calcification by changing the levels of calcification factors.
Collapse
Affiliation(s)
- Pan Liu
- Department of Nephrology, The Affiliated Hospital of Guizhou Medical University, Guizhou, China
| | - Xiang Xu
- Department of Nephrology, The Affiliated Baiyun Hospital of Guizhou Medical University, Guizhou, China
| | - YuFu Wang
- Department of Nephrology, The Affiliated Hospital of Guizhou Medical University, Guizhou, China
| | - XiaoNa Long
- Department of Nephrology, The Affiliated Baiyun Hospital of Guizhou Medical University, Guizhou, China
| | - XunJia Li
- Department of Nephrology, The Affiliated Baiyun Hospital of Guizhou Medical University, Guizhou, China
| | - HongYing Peng
- Department of Nephrology, The Affiliated Baiyun Hospital of Guizhou Medical University, Guizhou, China
| |
Collapse
|
2
|
New Therapeutics Targeting Arterial Media Calcification: Friend or Foe for Bone Mineralization? Metabolites 2022; 12:metabo12040327. [PMID: 35448514 PMCID: PMC9027727 DOI: 10.3390/metabo12040327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 03/31/2022] [Accepted: 04/03/2022] [Indexed: 01/27/2023] Open
Abstract
The presence of arterial media calcification, a highly complex and multifactorial disease, puts patients at high risk for developing serious cardiovascular consequences and mortality. Despite the numerous insights into the mechanisms underlying this pathological mineralization process, there is still a lack of effective treatment therapies interfering with the calcification process in the vessel wall. Current anti-calcifying therapeutics may induce detrimental side effects at the level of the bone, as arterial media calcification is regulated in a molecular and cellular similar way as physiological bone mineralization. This especially is a complication in patients with chronic kidney disease and diabetes, who are the prime targets of this pathology, as they already suffer from a disturbed mineral and bone metabolism. This review outlines recent treatment strategies tackling arterial calcification, underlining their potential to influence the bone mineralization process, including targeting vascular cell transdifferentiation, calcification inhibitors and stimulators, vascular smooth muscle cell (VSMC) death and oxidative stress: are they a friend or foe? Furthermore, this review highlights nutritional additives and a targeted, local approach as alternative strategies to combat arterial media calcification. Paving a way for the development of effective and more precise therapeutic approaches without inducing osseous side effects is crucial for this highly prevalent and mortal disease.
Collapse
|
3
|
Chao CT, Yeh HY, Tsai YT, Chuang PH, Yuan TH, Huang JW, Chen HW. Natural and non-natural antioxidative compounds: potential candidates for treatment of vascular calcification. Cell Death Discov 2019; 5:145. [PMID: 31754473 PMCID: PMC6853969 DOI: 10.1038/s41420-019-0225-z] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 09/23/2019] [Accepted: 09/27/2019] [Indexed: 12/18/2022] Open
Abstract
Vascular calcification (VC) is highly prevalent in patients with advanced age, or those with chronic kidney disease and diabetes, accounting for substantial global cardiovascular burden. The pathophysiology of VC involves active mineral deposition by transdifferentiated vascular smooth muscle cells exhibiting osteoblast-like behavior, building upon cores with or without apoptotic bodies. Oxidative stress drives the progression of the cellular phenotypic switch and calcium deposition in the vascular wall. In this review, we discuss potential compounds that shield these cells from the detrimental influences of reactive oxygen species as promising treatment options for VC. A comprehensive summary of the current literature regarding antioxidants for VC is important, as no effective therapy is currently available for this disease. We systematically searched through the existing literature to identify original articles investigating traditional antioxidants and novel compounds with antioxidant properties with regard to their effectiveness against VC in experimental or clinical settings. We uncovered 36 compounds with antioxidant properties against VC pathology, involving mechanisms such as suppression of NADPH oxidase, BMP-2, and Wnt/β-catenin; anti-inflammation; and activation of Nrf2 pathways. Only two compounds have been tested clinically. These findings suggest that a considerable opportunity exists to harness these antioxidants for therapeutic use for VC. In order to achieve this goal, more translational studies are needed.
Collapse
Affiliation(s)
- Chia-Ter Chao
- Department of Medicine, National Taiwan University Hospital BeiHu Branch, College of Medicine, National Taiwan University, Taipei, Taiwan
- Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
- Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Hsiang-Yuan Yeh
- School of Big Data Management, Soochow University, Taipei, Taiwan
| | - You-Tien Tsai
- Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Pei-Huan Chuang
- Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Tzu-Hang Yuan
- Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Jenq-Wen Huang
- Nephrology Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Huei-Wen Chen
- Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan
| |
Collapse
|
4
|
Goossens J, Courbebaisse M, Caudron E, Bahans C, Vacquerie V, Melchior J, Salle PV, Moesch C, Daudon M, Frocht V, Richette P, Ea HK, Guigonis V. Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases. Semin Arthritis Rheum 2017; 47:451-455. [PMID: 28779847 DOI: 10.1016/j.semarthrit.2017.05.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2017] [Revised: 05/10/2017] [Accepted: 05/30/2017] [Indexed: 01/11/2023]
Abstract
INTRODUCTION Tumoral calcinosis (TC) is a difficult-to-treat complication that can occur during several diseases such as dermatomyositis or genetic hyperphosphatemia. It is a painful and disabling condition that can lead to local complications including joint mobility reduction, cutaneous ulceration and superinfection. For the largest lesions, the treatment relies essentially on surgery. Intravenous sodium thiosulfate (STS) is efficient to treat calciphylaxis in patients undergoing hemodialysis. Local injections of STS seem efficient in superficial calcifications. OBJECTIVE To report the efficacy and safety of intra-lesional injections of STS in tumoral calcinosis. RESULTS We report two cases of successful intra-lesional injections of STS. A 44-year-old woman, with a history of dermatomyositis, presenting large subcutaneous calcifications in the right elbow, and a 42-year-old man, with a history of familial tumoral calcinosis, presenting large intramuscular calcifications in the right buttock, received weekly intra-lesional of 1-3g STS injections for 12 and 21 months, respectively. In both cases, the treatment relieved pain and greatly reduced the tumoral calcinosis with a very significant functional improvement without specific adverse effects. In case 1, TC size decreased from 28.7*56.0mm at baseline to 21.5*30.6mm at M12 treatment (59% reduction). In case 2, TC reduced from 167.5*204.3mm at baseline to 86.2*85.2mm at M21 treatment (79% reduction). CONCLUSION Local injection of STS could be a promising therapeutic strategy for large and deep TC lesions and could therefore be an alternative to surgery.
Collapse
Affiliation(s)
- J Goossens
- Service de rhumatologie, hôpital Lariboisière, centre Viggo Petersen, Paris, France
| | - M Courbebaisse
- AP-HP, Georges Pompidou European Hospital, Physiology Department, Paris Descartes University, and INSERM, Unit 1151, Paris, France
| | - E Caudron
- AP-HP, Hôpital Européen Georges Pompidou, Department of Pharmacy, Paris, France; Lip(Sys), Chimie analytique pharmaceutique EA 4041, Univ. Paris Sud, Université Paris-Saclay, Chatenay Malabry, France
| | - C Bahans
- Service de pédiatrie, Hopital de la Mère et de l'Enfant, Limoges, France
| | - V Vacquerie
- Service de chirurgie pédiatrique, Hopital de la Mère et de l'Enfant, Limoges, France
| | - J Melchior
- Service de Rhumatologie, Hopitaux de Brabois, Vandoeuvre les Nancy, France
| | - P Vergne Salle
- Service de Rhumatologie, Hôpital Dupuytren, Limoges, France
| | - C Moesch
- Service de Pharmacologie-toxicologie, Hôpital Dupuytren, Limoges, France
| | - M Daudon
- Service des explorations fonctionnelles, Hôpital Tenon, Paris, France
| | - V Frocht
- Service des explorations fonctionnelles, Hôpital Tenon, Paris, France
| | - P Richette
- Service de rhumatologie, hôpital Lariboisière, centre Viggo Petersen, Paris, France
| | - Hang-Korng Ea
- Service de rhumatologie, hôpital Lariboisière, centre Viggo Petersen, Paris, France.
| | - V Guigonis
- Service de pédiatrie, Hopital de la Mère et de l'Enfant, Limoges, France.
| |
Collapse
|
5
|
Guigonis V, Bahans C, Ea K, Bourrat E, Lienhardt A, Chabre O, Jost J, Mutar H, Ratsimbazafy V, Linglart A. Treatment of heterotopic ossifications secondary to pseudohypoparathyroid. ANNALES D'ENDOCRINOLOGIE 2015; 76:183-4. [PMID: 25916756 DOI: 10.1016/j.ando.2015.03.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 03/17/2015] [Indexed: 12/29/2022]
Affiliation(s)
- Vincent Guigonis
- Pédiatrie, CHU de Limoges, Limoges, France; CHREC, CHU de Limoges, Limoges, France.
| | - Claire Bahans
- Pédiatrie, CHU de Limoges, Limoges, France; CHREC, CHU de Limoges, Limoges, France
| | - Korng Ea
- Rhumatologie, Lariboisière, AP-HP, Paris, France
| | | | - Anne Lienhardt
- Pédiatrie, CHU de Limoges, Limoges, France; CHREC, CHU de Limoges, Limoges, France
| | | | | | | | | | - Agnès Linglart
- Endocrinologie pédiatrique, Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
| |
Collapse
|
6
|
Xu J, Bai Y, Jin J, Zhang J, Zhang S, Cui L, Zhang H. Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a time-dependent manner. Exp Ther Med 2015; 9:1028-1034. [PMID: 25667672 PMCID: PMC4316900 DOI: 10.3892/etm.2015.2215] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Accepted: 12/15/2014] [Indexed: 01/02/2023] Open
Abstract
Vascular calcification, a common complication in patients with chronic kidney disease, involves a variety of mechanisms associated with the regulation of calcification-associated factors. Previous clinical studies have indicated that magnesium is involved in the reduction of vascular calcification; however, the mechanism underlying this process remains unknown. The aim of the present study was to investigate the effects of magnesium on β-glycerophosphate (β-GP)-induced calcification and the underlying mechanisms. Primary rat vascular smooth muscle cells (VSMCs) were exposed to 10 mM β-GP in medium with or without the addition of 3 mM magnesium or 2-aminoethoxy-diphenylborate (2-APB; an inhibitor of magnesium transport), for a 14-day period. Calcium deposition and alkaline phosphatase (ALP) activity were measured by Alizarin red staining, quantification of calcium and enzyme-linked immunosorbent assay. The expression levels of core-binding factor α-1 (Cbfα1), matrix Gla protein (MGP) and osteopontin (OPN) were determined by reverse transcription-polymerase chain reaction or western blot analysis, following incubation for 0, 3, 6, 10 and 14 days with the different media. VSMC calcification and ALP activity was reduced significantly in the high-magnesium medium compared with the calcification medium, during the 14-day incubation. The magnesium-induced changes in the VSMCs included a β-GP-induced downregulation of Cbfα1 by day 3 of incubation, an effect that was gradually enhanced over the 14-day period. By contrast, magnesium produced notable increases in MGP and OPN expression levels, with an opposite pattern to that observed in the Cbfα1 expression levels. However, the addition of 2-APB appeared to inhibit the protective effect of magnesium on the VSMCs. Therefore, magnesium was able to effectively reduce β-GP-induced calcification in rat VSMCs by regulating the expression levels of calcification-associated factors in a time-dependent manner.
Collapse
Affiliation(s)
- Jinsheng Xu
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| | - Yaling Bai
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| | - Jingjing Jin
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| | - Junxia Zhang
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| | - Shenglei Zhang
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| | - Liwen Cui
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| | - Huiran Zhang
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
| |
Collapse
|
7
|
Li ZJ, Lu CT, Feng ZQ, Zhao QT, Zhou ZY, Lai RF. Antigen-extracted xenogeneic cancellous bone graft with recombinant human bone morphogenetic protein-2 enhances bone regeneration in repair of mandibular defect in rabbits. Kaohsiung J Med Sci 2014; 31:18-25. [PMID: 25600916 DOI: 10.1016/j.kjms.2014.10.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 08/03/2014] [Accepted: 09/11/2014] [Indexed: 01/08/2023] Open
Abstract
The effects of a large-piece of xenogeneic bone that was separated from healthy pigs as a scaffold for the repair of a mandibular defect was investigated, and the applicability of antigen-extracted xenogeneic cancellous bone (AXCB) soaked with recombinant human bone morphogenetic protein-2 (rhBMP-2) in bone defect repair was assessed. Mandibular defects were created in 48 New Zealand rabbits, and the animals were randomly divided into four groups, in which the mandibular defects were grafted with AXCB, AXCB soaked with rhBMP-2, and autograft bone, or left blank. An equal number of animals from each group were classified into three time points (4, 8, and 12 weeks) after surgery for gross pathological observation, hematoxylin and eosin (H and E) staining, radiographic examination, and bone density measurement. H and E staining revealed that the area percentage of bone regeneration in the group of the AXCB/rhBMP-2 graft was 27.72 ± 4.68, 53.90 ± 21.92, and 77.35 ± 9.83 at 4 weeks, 8 weeks, and 12 weeks, respectively. These results were better than those of the autogenous bone graft, suggesting that the group of the AXCB/rhBMP-2 graft achieved a good osteogenic effect. With regard to the AXCB graft without rhBMP-2, the area percentage of bone regeneration was only 14.03 ± 5.02, 28.49 ± 11.35, and 53.90 ± 21.92. Therefore, the osteogenic effect of the AXCB/rhBMP-2 graft was demonstrated to have the best effect. In the group of the AXCB/rhBMP-2 graft, the area percentage of bone regeneration increased, and the implanted materials were gradually degraded and replaced by autogenous bone regeneration over time. We conclude that the AXCB graft soaked with rhBMP-2 showed good osteogenic effect in the repair of bone defects and good biocompatibility. AXCB serves as a good carrier of rhBMP-2, which promotes bone formation.
Collapse
Affiliation(s)
- Ze-jian Li
- Medical Centre of Stomatology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Chun-ting Lu
- Department of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Zhi-qiang Feng
- Medical Centre of Stomatology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Qing-tong Zhao
- Medical Centre of Stomatology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Zhi-ying Zhou
- Medical Centre of Stomatology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
| | - Ren-fa Lai
- Medical Centre of Stomatology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China.
| |
Collapse
|